LitAlert ~~ GeneLit.com

    • Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience.
    • Moubarak M, Harter P, Ataseven B, Traut A, Welz J, Baert T, Heitz F.
    • Gynecol Oncol Rep. 2022 Feb 2 [eCollection 2022 Apr];40:100939. doi: 10.1016/j.gore.2022.100939.
    • Hereditary Breast and Ovarian Cancer: An Updated Primer for OB/GYNs.
    • Bellcross CA.
    • Obstet Gynecol Clin North Am. 2022 Mar;49(1):117-147. doi: 10.1016/j.ogc.2021.11.005.
    • Review
    • Evaluation of Hereditary/Familial Breast Cancer Patients with Multigene Targeted Next Generation Sequencing Panel and MLPA Analysis in Turkey.
    • Bora E, Caglayan AO, Koc A, Cankaya T, Ozkalayci H, Kocabey M, Kemer D, Aksoy S, Alicikus ZA, Akin IB, Durak MG, Gurel D, Yavuzsen T, Sevinc A, Somali I, Gorken I, Balci P, Karaoglu A, Saydam S, Ulgenalp A.
    • Cancer Genet. 2022 Feb 16. doi: 10.1016/j.cancergen.2022.02.006. Epub ahead of print.
    • Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    • Tattersall A, Ryan N, Wiggans AJ, Rogozinska E, Morrison J.
    • Cochrane Database Syst Rev. 2022 Feb 16;2:CD007929. doi: 10.1002/14651858.CD007929.pub4.
    • Review
    • Earlier decisions on breast and ovarian surgery reduce cancer in women at high risk.
    • Saul H, Gursul D, Cassidy S, Evans G.
    • BMJ. 2022 Feb 15;376:o258. doi: 10.1136/bmj.o258.
    • Research news

    Original research:

    Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers.

    • Update Breast Cancer 2021 Part 5 - Advanced Breast Cancer.
    • Lüftner D, Schütz F, Stickeler E, Fasching PA, Janni W, Kolberg-Liedtke C, Kolberg HC, Thomssen C, Müller V, Fehm TN, Belleville E, Bader S, Untch M, Welslau M, Thill M, Tesch H, Ditsch N, Lux MP, Wöckel A, Aktas B, Schneeweiss A, Würstlein R, Hartkopf AD.
    • Geburtshilfe Frauenheilkd. 2022 Feb 11 [eCollection 2022 Feb];82(2):215-225. doi: 10.1055/a-1724-9569.